VIDEO: Tremfya induces increased rates of clinical remission in Crohn’s
Click Here to Manage Email Alerts
In a video exclusive, Jan Wehkamp, MD, vice president, gastroenterology global disease area leader at Janssen Pharmaceuticals, reported positive long-term data evaluating Tremfya for the treatment of patients with Crohn’s disease.
Following previously reported interim results, the phase 2 GALAXI 1 study showed rates of clinical remission increased from 12 to 48 weeks (65%) with comparable safety data. Though not currently approved for the treatment of CD in the U.S., phase 3 trials for Tremfya (guselkumab, Janssen) among patients with moderate to severe CD as well as moderate to severe ulcerative colitis are enrolling and ongoing.
“These results are important because they mark the first long-term data evaluating Tremfya anti-IL-23 in moderately to severely active Crohn’s disease,” Wehkamp said. “More importantly, we hope this data can help inform physicians around the world about Janssen’s ongoing research in this disease area and our commitment to investigate pathway signs in the development of novel therapy that can potentially address the multifaceted nature of immune-mediated diseases.”
Read more about
Click Here to Manage Email Alerts